» Articles » PMID: 18485400

The Causal Role of Cigarette Smoking in Bladder Cancer Initiation and Progression, and the Role of Urologists in Smoking Cessation

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 2008 May 20
PMID 18485400
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Cigarette smoking is a well established risk factor for bladder cancer. We characterize the changing impact of this exposure throughout the course of bladder cancer from incidence through progression. We also discuss how understanding the risk of bladder cancer attributable to smoking can help urologists effectively communicate with their patients and influence smoking cessation in their patients.

Materials And Methods: A review using the MEDLINE database from 1975 through 2007 was performed to search for studies from the epidemiological and medical literature on cigarette smoking and bladder cancer.

Results: Cigarette smoking accounts for up to 50% of all incident bladder cancer cases, an attributable fraction that may be increasing. The general public is not informed of the association between cigarette smoking and bladder cancer, and physicians do a poor job of counseling patients regarding this risk. Smoking cessation has proven beneficial in decreasing the risk of many smoking related illnesses, including bladder cancer. Simple physician interventions can be effective in triggering patient attempts at quitting smoking.

Conclusions: Bladder cancer is causally related to cigarette smoking but this knowledge may not be well disseminated to patients. Furthermore, cigarette smoking cessation decreases bladder cancer risk and may decrease the recurrence of superficial bladder cancer. Urologists have a vital role in influencing patient knowledge of their smoking risk and in encouraging smoking cessation.

Citing Articles

Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess.

Huang Y, Xu M, Ma X, Wang W, Shen C, Liu F Front Pharmacol. 2024; 15:1503154.

PMID: 39712492 PMC: 11659001. DOI: 10.3389/fphar.2024.1503154.


Bladder cancer incidence and mortality among men with and without castration therapy for prostate cancer - a nation-wide cohort study.

Hyldgaard J, Norgaard M, Hjort P, Jensen J Acta Oncol. 2024; 63:746-754.

PMID: 39319939 PMC: 11445587. DOI: 10.2340/1651-226X.2024.40969.


Effect of smoking on the recurrence and progression of non-muscle-invasive bladder cancer.

Chen C, Fan G, Li P, Yang E, Jing S, Shi Y Clin Transl Oncol. 2024; .

PMID: 39266874 DOI: 10.1007/s12094-024-03694-z.


Lung Metastases Versus Second Primary Lung Cancers in Patients with Primary Urothelial Carcinoma of the Bladder: A National Population-Based Assessment.

Taylor J, Weiner A, Wang B, Balar A, Steinberg G, Matulewicz R Bladder Cancer. 2024; 7(3):347-354.

PMID: 38993612 PMC: 11181803. DOI: 10.3233/BLC-210008.


Sexual dimorphism in bladder cancer: a review of etiology, biology, diagnosis, and outcomes.

Zhu S, Zhao H Front Pharmacol. 2024; 14:1326627.

PMID: 38283839 PMC: 10811034. DOI: 10.3389/fphar.2023.1326627.